Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Exact Sciences : Infographic

10/27/2020 | 06:35am EST

EXACT SCIENCES TO ACQUIRE THRIVE

Creating a Leader in Blood-BasedMulti-Cancer Screening

Transforming the

Accelerating the

future of cancer

approval, availability,

diagnostics with a

and adoption of

premier R&D team

multi-cancer screening

Adds Thrive's R&D groups

Leverages Exact Sciences'

specializing in liquid biopsy

proven clinical and regulatory

Complements and enhances

teams, scaled laboratory and

IT capabilities, and best-in-

Exact Sciences' robust clinical

class sales and marketing

and evidence generation

organization

capabilities

Demonstrating

capabilities as a research and commercialization partner-of-choice

Positions Exact Sciences as a leader in a $25 billion+ market

Enhances scientific rigor to bring tests to patients at every step of their cancer journey

Kevin Conroy

Chairman and Chief Executive Officer

Exact Sciences

"The acquisition of Thrive is a giant leap toward ensuring blood-based,multi-cancer screening becomes a reality and eventually, the standard of care. By combining the expertise of both organizations, we believe we can bring this powerful technology to patients faster."

David Daly

Chief Executive Officer

Thrive Earlier Detection

"We are eager to collaborate with and benefit from Exact Sciences' expertise. We are energized to contribute meaningfully to advancing the fight against cancer, and believe that together we will enable broader, quicker adoption of our test."

ABOUT

Thrive is dedicated to incorporating earlier cancer detection into routine medical care, and has conducted a first-of-its-kind10,000-patient, prospective, interventional study with an early version of CancerSEEK.

Headquartered in

Cambridge, MA

Focused on developing

CancerSEEK

Rooted in work from

The Vogelstein Lab at Johns Hopkins University

DETECT-A Results

  • More than doubled the number of cancers first detected through screening
  • 65% of cancers detected were in early stages
  • Identified 10 different cancer types, including 7 with no recommended screening guidelines

TRANSACTION SNAPSHOT

TOTAL ADDRESSABLE MARKET

up to $2.15 billion

$25B+

$1.7 billion in cash and stock payable at closing

Additional $450 million payable based upon the

achievement of certain milestones

$18B

$3.5B

Path to Close:

Q1 '21

Anticipated to close in first quarter of 2021,

subject to customary closing conditions

and regulatory approvals

Cologuard

Oncotype

Multi-Cancer

EXACT SCIENCES ALSO ACQUIRES

DNA quantity & quality

Genetic & epigenetic data

Detection cost

preserved

simultaneously generated

significantly reduced

POSITIONING EXACT SCIENCES AT THE FOREFRONT OF AN

INCREDIBLE OPPORTUNITY TO SERVE PATIENTS AND IMPACT LIVES

Cautionary Statement

This communication contains statements, including statements regarding the pending acquisition of Thrive by Exact Sciences, that are forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are intended to be covered by the "safe harbor" created by those sections. Forward- looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "estimate," "goal," "anticipate" "project" or other comparable terms. All statements other than statements of historical facts included in this communication regarding strategies, prospects, financial condition, operations, costs, plans, objectives and the pending acquisition of Thrive are forward-looking statements. Examples of forward-looking statements include, among others, statements regarding expected future operating results, anticipated results of sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, the anticipated results of product development efforts,

the anticipated benefits of the pending acquisition of Thrive, including estimated synergies and other financial impacts, and the expected timing of completion of the transaction. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of Exact Sciences' business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on operations, including supply chain, and the demand for products and services; the ability to efficiently and flexibly manage

the business amid uncertainties related to COVID-19; the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the success of our efforts to facilitate patient access to Cologuard® via telehealth; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued

by various organizations such as the U.S. Preventive Services Task Force, the American Society of Clinical Oncology, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; the ability to successfully develop new products and services and assess potential market opportunities; the ability to effectively enter into and utilize strategic partnerships, such as through the Restated Promotion Agreement with Pfizer, Inc., and acquisitions; success establishing and maintaining collaborative, licensing and supplier arrangements; the ability of Exact Sciences and Thrive to maintain regulatory approvals and comply with applicable regulations; the ability to manage an international business and the expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our efforts to hedge such effects; the possibility that the anticipated benefits from our business acquisitions (including the pending acquisition of Thrive) cannot be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of acquired businesses' (including Thrive's) operations will be greater than expected and the possibility of disruptions to our business during integration efforts and strain on management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; the ability of Exact Sciences and Thrive to receive the required regulatory approvals for the pending merger and to satisfy the conditions to the closing of the transaction on a timely basis or at all; the occurrence of events that may give rise to a right of one or both of Exact Sciences and Thrive to terminate the merger agreement; possible negative effects of the announcement or the consummation of the pending acquisition of Thrive on the market price of Exact Sciences' Common Stock and/or on Exact Sciences' and/or Thrive's respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; risks associated with contracts containing consent and/or other provisions that may be triggered by the pending acquisition of Thrive; risks associated with potential transaction-related litigation; the ability of Thrive and the combined company to retain and hire key personnel. There can be no assurance that the pending acquisition of Thrive will in fact be consummated in the manner described or at all. For additional information on identifying factors that may cause actual results, conditions or events to vary materially from those stated in forward-looking statements, please see Exact Sciences' reports on Forms 10-K,10-Q and 8-K filed with or furnished to the SEC and other written statements made by Exact Sciences and/or Thrive from time to time. You are urged to consider those risks and uncertainties in evaluating our forward-looking statements. All subsequent written and oral forward- looking statements attributable to Exact Sciences or to persons acting on behalf of Exact Sciences are expressly qualified in their entirety by the applicable cautionary statements. Readers are further cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, Exact Sciences undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Disclaimer

EXACT Sciences Corporation published this content on 27 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2020 11:34:00 UTC


© Publicnow 2020
All news about EXACT SCIENCES CORPORATION
01/15EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/13EXACT SCIENCES : Licenses Targeted Digital Sequencing Method in Cancer Screening
MT
01/12EXACT SCIENCES : Oppenheimer Adjusts Price Target for Exact Sciences to $161 Fro..
MT
01/11INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Sale of Guidewire Soft..
MT
01/11SECTOR UPDATE : Narrow Rise for Most Health Care Stocks
MT
01/11EXACT SCIENCES : Projects Q4 Revenue Above Street Forecasts
MT
01/08EXACT SCIENCES : EXAS) Insider Makes Significant Share Sale
MT
01/07INSIDER TRENDS : Exact Sciences Insider Extends 90-Day Selling Trend
MT
01/05Jefferies, Exxon rise; Exact Sciences, WW International fall
AQ
01/05EXACT SCIENCES : Sees Q4 Revenue To Exceed Market Expectations
MT
More news
Financials (USD)
Sales 2020 1 465 M - -
Net income 2020 -396 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -54,1x
Yield 2020 -
Capitalization 23 668 M 23 668 M -
EV / Sales 2020 16,0x
EV / Sales 2021 12,9x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 149,33 $
Last Close Price 148,83 $
Spread / Highest target 10,9%
Spread / Average Target 0,34%
Spread / Lowest Target -48,9%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION12.33%23 668
GUARDANT HEALTH, INC.24.10%15 990
INVITAE CORPORATION33.60%9 870
ADAPTIVE BIOTECHNOLOGIES CORPORATION13.88%9 210
BGI GENOMICS CO., LTD.17.29%9 087
IOVANCE BIOTHERAPEUTICS, INC.9.76%7 471